Radioiodinated Metaiodobenzylguanidine in Neuroblastoma: Influence of High Dose on Tumour Site Detection

Overview

Journal Eur J Nucl Med

Specialty Nuclear Medicine

Date 1995 Oct 1

PMID 8542903

Citations 5

Authors

F Giammarile

J Lumbroso

M Ricard

B Aubert

O Hartmann

M Schlumberger

C Parmentier

Affiliations

Soon will be listed here.

Abstract

For more than a decade radioiodinated metaiodobenzylguanidine (mIBG) has been commonly used for neuroblastoma imaging. The accuracy of this scintigraphic method in detecting both primary and secondary tumour sites is crucial when evaluating the extent of disease. The aim of our study was to assess the impact of high-activity mIBG scintigraphy on neuroblastoma staging. Eighteen scans (TS) were obtained in 15 children after a therapeutic dose of iodine-131 mIBG and compared to diagnostic mIBG scans (DS) (in eight cases with 131I-mIBG and in ten cases with 123I-mIBG). The superiority of TS over DS was confirmed by the overall results: a total of 220 lesions were disclosed with TS and 171 with DS. However, in only one case did the TS findings, namely skeletal involvement not evidenced on corresponding DS, have an impact on clinical staging. In contrast, neither TS nor DS detected proven bone involvement in four patients. The dose-related sensitivity of mIBG scintigraphy in detecting neuroblastoma tumour sites was confirmed. The ultimate impact of high-dose scans on neuroblastoma management, however, seems limited.

Citing Articles

Diagnostic Use of Post-therapy I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma.

Wakabayashi H, Kayano D, Inaki A, Araki R, Kuroda R, Akatani N Diagnostics (Basel). 2020; 10(9).

PMID: 32887257 PMC: 7555271. DOI: 10.3390/diagnostics10090663.

Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study.

Piccardo A, Lopci E, Conte M, Garaventa A, Foppiani L, Altrinetti V Eur J Nucl Med Mol Imaging. 2011; 39(1):57-71.

PMID: 21932116 DOI: 10.1007/s00259-011-1938-2.

Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Dunphy M, Lewis J J Nucl Med. 2009; 50 Suppl 1:106S-21S.

PMID: 19380404 PMC: 2963172. DOI: 10.2967/jnumed.108.057281.

Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.

Dubois S, Matthay K Nucl Med Biol. 2008; 35 Suppl 1:S35-48.

PMID: 18707633 PMC: 2633223. DOI: 10.1016/j.nucmedbio.2008.05.002.

EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy.

Giammarile F, Chiti A, Lassmann M, Brans B, Flux G Eur J Nucl Med Mol Imaging. 2008; 35(5):1039-47.

PMID: 18274745 DOI: 10.1007/s00259-008-0715-3.

References

Wilson L, Draper G . Neuroblastoma, its natural history and prognosis: a study of 487 cases. Br Med J. 1974; 3(5926):301-7. PMC: 1611711. DOI: 10.1136/bmj.3.5926.301. View

Berthold F, Waters W, Sieverts H, Linden A . Immunoscintigraphic imaging of mIBG-negative metastases in neuroblastoma. Am J Pediatr Hematol Oncol. 1990; 12(1):61-2. DOI: 10.1097/00043426-199021000-00011. View

Parisi M, Matthay K, Huberty J, Hattner R . Neuroblastoma: dose-related sensitivity of MIBG scanning in detection. Radiology. 1992; 184(2):463-7. DOI: 10.1148/radiology.184.2.1620849. View

Hoefnagel C, de Kraker J, Valdes Olmos R, VOUTE P . 131I-MIBG as a first-line treatment in high-risk neuroblastoma patients. Nucl Med Commun. 1994; 15(9):712-7. DOI: 10.1097/00006231-199409000-00008. View

Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C . Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med. 1987; 28(12):1888-91. View

Schlumberger M, Arcangioli O, Piekarski J, TUBIANA M, Parmentier C . Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med. 1988; 29(11):1790-4. View

Young Jr J, Ries L, Silverberg E, Horm J, Miller R . Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer. 1986; 58(2 Suppl):598-602. DOI: 10.1002/1097-0142(19860715)58:2+<598::aid-cncr2820581332>3.0.co;2-c. View

Corbett R, Olliff J, Fairley N, Moyes J, Husband J, Pinkerton R . A prospective comparison between magnetic resonance imaging, meta-iodobenzylguanidine scintigraphy and marrow histology/cytology in neuroblastoma. Eur J Cancer. 1991; 27(12):1560-4. DOI: 10.1016/0277-5379(91)90415-a. View

Gelfand M . Meta-iodobenzylguanidine in children. Semin Nucl Med. 1993; 23(3):231-42. DOI: 10.1016/s0001-2998(05)80104-7. View

10.

Bonnin F, Lumbroso J, Tenenbaum F, Hartmann O, Parmentier C . Refining interpretation of MIBG scans in children. J Nucl Med. 1994; 35(5):803-10. View

11.

Parisi M, Greene M, Dykes T, Moraldo T, Sandler E, Hattner R . Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma. Invest Radiol. 1992; 27(10):768-73. DOI: 10.1097/00004424-199210000-00003. View

12.

Preisman R, Halpern S . Detection of metastatic thyroid carcinoma after the administration of a therapeutic dose of 131-iodine. Eur J Nucl Med. 1978; 3(1):69-70. DOI: 10.1007/BF00253481. View

13.

Gordon I, Peters A, Gutman A, Morony S, Pritchard J . Skeletal assessment in neuroblastoma--the pitfalls of iodine-123-MIBG scans. J Nucl Med. 1990; 31(2):129-34. View

14.

Yeh S, Larson S, Burch L, Kushner B, LaQuaglia M, Finn R . Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities. J Nucl Med. 1991; 32(5):769-76. View

15.

Shulkin B, Shapiro B, Hutchinson R . Iodine-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma. J Nucl Med. 1992; 33(10):1735-40. View

16.

Lumbroso J, Guermazi F, Hartmann O, Coornaert S, Rabarison Y, Leclere J . Meta-iodobenzylguanidine (mIBG) scans in neuroblastoma: sensitivity and specificity, a review of 115 scans. Prog Clin Biol Res. 1988; 271:689-705. View

17.

Hattner R, Huberty J, Engelstad B, Gooding C, Ablin A . Localization of m-iodo(131I)benzylguanidine in neuroblastoma. AJR Am J Roentgenol. 1984; 143(2):373-4. DOI: 10.2214/ajr.143.2.373. View

18.

Bourliere Najean B, Siles S, Panuel M, Cammilleri S, Faure F, Devred P . Value of MRI and MIBG-I123 scintigraphy in the diagnosis of spinal bone marrow involvement in neuroblastoma in children. Pediatr Radiol. 1992; 22(6):443-6. DOI: 10.1007/BF02013507. View

19.

Wieland D, Wu J, Brown L, Mangner T, Swanson D, BEIERWALTES W . Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med. 1980; 21(4):349-53. View

20.

Garty I, Friedman A, Sandler M, Kedar A . Neuroblastoma: imaging evaluation by sequential Tc-99m MDP, I-131 MIBG, and Ga-67 citrate studies. Clin Nucl Med. 1989; 14(7):515-22. DOI: 10.1097/00003072-198907000-00009. View